Results 161 to 170 of about 10,778 (201)

Effectiveness of caplacizumab in the first-line treatment for acquired thrombotic thrombocytopenic purpura: single center experience. [PDF]

open access: yesTher Adv Hematol
Belakova KM   +13 more
europepmc   +1 more source

A 30-minute intravenous infusion of rituximab is safe and cost-effective (SpeedR). [PDF]

open access: yesAnn Hematol
Wahlin BE   +5 more
europepmc   +1 more source

Home - About - Disclaimer - Privacy